Acting FDA Commissioner to Provide an Overview on the FDA's Initiatives for Protecting and Advancing Public Health (PR Newswire via Yahoo! Finance)
Acting FDA Commissioner, Andrew C. von Eschenbach, M.D. will deliver a keynote address on Wednesday, August 9th at IBC's 11th Annual Drug Discovery Technology & Development World Congress.

Antares Submits 510(k) with a Branded Human Growth Hormone (Business Wire via Yahoo! Finance)
EWING, N.J.----Aug. 9, 2006--Antares Pharma, Inc. has submitted a Premarket Notification 510 to the FDA announcing the Company's intent to market a needle-free injection system for use with a branded human growth hormone that is currently approved and marketed in the United States.

MacuSight Announces FDA Acceptance Of IND For Novel Ophthalmic Drug Candidate (Medical News Today)
MacuSight, Inc., a developerof innovative therapeutics for the treatment of severe ocular diseases andconditions, today announced that the United States Food and DrugAdministration (FDA) has accepted the company's Investigational New Drug(IND) application for its proprietary formulation of sirolimus (rapamycin). [click link for full article]